Russell Investments Group
TRDA icon

Russell Investments Group’s Entrada Therapeutics TRDA Stock Holding History

Russell Investments Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Buy
23,450
+11,817
+102% +$113K ﹤0.01% 3236
2026
Q1 		$147K Buy
11,633
+62
+0.5% +$711 ﹤0.01% 2959
2025
Q4 		$119K Buy
11,571
+2,763
+31% +$23.3K ﹤0.01% 2998
2025
Q3 		$51.1K Buy
8,808
+3,707
+73% +$21.7K ﹤0.01% 3285
2025
Q2 		$34.3K Sell
5,101
-53
-1% -$426 ﹤0.01% 3071
2025
Q1 		$46.6K Buy
5,154
+334
+7% +$4.16K ﹤0.01% 2926
2024
Q4 		$83.3K Buy
4,820
+4,811
+53,456% +$87.2K ﹤0.01% 2721
2024
Q3 		$144 Sell
9
-2,051
-100% -$32.3K ﹤0.01% 3659
2024
Q2 		$29.4K Buy
2,060
+2,051
+22,789% +$29.2K ﹤0.01% 2880
2024
Q1 		$128 Hold
9
– – ﹤0.01% 3292
2023
Q4 		$136 Hold
9
– – ﹤0.01% 3192
2023
Q3 		$142 Sell
9
-6,744
-100% -$106K ﹤0.01% 3507
2023
Q2 		$102K Buy
+6,753
New +$93K ﹤0.01% 2599

Other funds holding TRDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group's TRDA Position: Q2 2026 in Review

Russell Investments Group increased its Entrada Therapeutics (TRDA) stake by 102% in Q2 2026, buying an estimated $113K and bringing the position to 23,450 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3236.

Russell Investments Group first reported a position in TRDA in Q2 2023 and has held it in 13 quarters since. 38 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Russell Investments Group held 23,450 shares of Entrada Therapeutics worth $173K as of Q2 2026.
  • Russell Investments Group bought 11,817 Entrada Therapeutics shares in Q2 2026, an estimated $113K.
  • Entrada Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3236 holding.
  • Russell Investments Group first reported a position in Entrada Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 38 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.